RxDoctor Payments Data

David Smith, MD

Pulmonary Disease · Bowling Green, KYNPI 1871584052

Payments from drug & device makers

$933in general payments, 2019–2025

Across 46 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$166
  • AbbVie$82
  • Actelion Pharmaceuticals US, Inc.$71
  • GSK$59
  • Sunovion Pharmaceuticals Inc.$52
  • Shockwave Medical, Inc$47
  • plus $456 from 19 others

What the payments were for

  • Food & beverage$89596%
  • Education$384%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$933 in reported general payments places this provider in the 20th percentile of 226 pulmonary disease providers in Kentucky.

See all pulmonary disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$10,140
Medicare patients
94
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$64,488
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$34,557
Stiolto RespimatTiotropium Br/Olodaterol Hcl30$24,213
Spiriva RespimatTiotropium Bromide18$14,532
Breo ElliptaFluticasone/Vilanterol20$10,212
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,302
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$4,818
SymbicortBudesonide/Formoterol Fumarate12$4,477
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$4,173
Albuterol Sulfate HfaAlbuterol Sulfate48$1,963
Ventolin HfaAlbuterol Sulfate12$733
Montelukast Sodium19$311
Prednisone25$122
Furosemide11$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$59$81,00291 claims
AstraZenecaBreztri Aerosphere, Symbicort$27$39,03447 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$166$38,74548 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 226 pulmonary disease providers in Kentucky.

Other pulmonary disease in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →